| Undiscounted life-years | Total Costs | Total QALYs | ICER (£) | Prob Tx CE at £20k | Undiscounted life-years | Total Costs | Total QALYs | ICER (£) | Prob Tx CE at £20k | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | ||||||||||
| 5% risk | |||||||||||
| No Tx | 23.66 | £2,910 | 12.93 | 50% | 26.16 | £3,346 | 13.17 | 49% | |||
| Tx | 23.78 | £4,034 | 12.99 | £20,524 | 50% | 26.30 | £4,465 | 13.23 | £19,978 | 51% | |
| 10% risk | |||||||||||
| No Tx | 22.84 | £4,169 | 12.52 | 15% | 25.24 | £5,241 | 12.73 | 12% | |||
| Tx | 23.03 | £5,105 | 12.61 | £10,017 | 85% | 25.46 | £6,092 | 12.83 | £8,635 | 88% | |
| 15% risk | |||||||||||
| No Tx | 22.09 | £5,348 | 12.14 | 6% | 24.41 | £6,991 | 12.33 | 5% | |||
| Tx | 22.34 | £6,107 | 12.26 | £5,969 | 94% | 24.69 | £7,602 | 12.46 | £4,610 | 95% | |
| 20% risk | |||||||||||
| No Tx | 21.41 | £6,443 | 11.78 | 3% | 23.67 | £8,621 | 11.96 | 3% | |||
| Tx | 21.70 | £7,062 | 11.93 | £3,993 | 97% | 23.99 | £9,035 | 12.12 | £2,566 | 97% | |
Note that values shaded red are above the NICE cost effectiveness threshold of £20,000 per QALY
Abbreviations: CE = cost effective, 20k = £20,000, ICER = incremental cost effectiveness ratio, No Tx = No treatment, QALYS = quality adjusted life-years, Tx = treatment.
From: Evidence review for initiating treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.